Literature DB >> 20352247

Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Joerg-Patrick Stübgen1, Annette Stipp.   

Abstract

Only isolated prospective studies have attempted to chart the natural history of facioascapulohumeral muscular dystrophy (FSHD), a benign myopathy with notoriously variable clinical manifestations and progression. This 10-year prospective study was performed to document by simple clinical methods the natural history of 16 patients with moderately advanced FSHD. Limb strength was evaluated by the bedside manual muscle test. Global weakness was documented as a composite average muscle score (AMS). Limb function was evaluated by a non-linear grading system of important functional milestones. A scale of activities of daily living (ADL) was used to assess disability across multiple functional domains in a home environment. Six-monthly evaluations determined a linear deterioration of the mean AMS that reached statistical significance from baseline at the 5-year interval. Half of patients showed a functional decline of the arms by one grade. All patients maintained useful hand function. Three quarters of patients suffered functional decline of the legs, commonly by one grade. All patients remained ambulant. Interval analyses showed a linear deterioration of the mean ADL score that reached statistical significance from baseline at the 5-year interval. Functional deterioration was mostly due to impaired shoulder girdle activities. This study of a relatively homogeneous subgroup of FSHD patients showed a predictable rate of clinical progression in a muscle disease with a notoriously variable clinical presentation and outcome. Natural history data obtained in this study could serve as positive controls for future therapeutic trials in this patient population. The chosen clinical parameters proved useful tools for charting clinical disease progression. Functional tests proved advantageous, because decline was based partly on patient self-reports, thereby improving time and cost effectiveness.

Entities:  

Mesh:

Year:  2010        PMID: 20352247     DOI: 10.1007/s00415-010-5544-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Manual muscle testing.

Authors:  J R Mendell; J Florence
Journal:  Muscle Nerve       Date:  1990       Impact factor: 3.217

2.  Functional testing.

Authors:  R T Moxley
Journal:  Muscle Nerve       Date:  1990       Impact factor: 3.217

3.  Thoracoscapular fusion in facioscapulohumeral dystrophy: clinical review of a new surgical method.

Authors:  R S Twyman; G D Harper; M A Edgar
Journal:  J Shoulder Elbow Surg       Date:  1996 May-Jun       Impact factor: 3.019

4.  A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

5.  Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.

Authors:  J R Mendell; M A Province; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; K K Kaiser; W King; J Robison
Journal:  Arch Neurol       Date:  1987-08

6.  Reliability of the activities of daily living scale and its use in telephone interview.

Authors:  D Shinar; C R Gross; K S Bronstein; E E Licata-Gehr; D T Eden; A R Cabrera; I G Fishman; A A Roth; J A Barwick; S C Kunitz
Journal:  Arch Phys Med Rehabil       Date:  1987-10       Impact factor: 3.966

7.  Facioscapulohumeral muscular dystrophy in the Dutch population.

Authors:  G W Padberg; R R Frants; O F Brouwer; C Wijmenga; E Bakker; L A Sandkuijl
Journal:  Muscle Nerve Suppl       Date:  1995

8.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.

Authors:  K E Personius; S Pandya; W M King; R Tawil; M P McDermott
Journal:  Phys Ther       Date:  1994-03

9.  ADL status in stroke: relative merits of three standard indexes.

Authors:  G E Gresham; T F Phillips; M L Labi
Journal:  Arch Phys Med Rehabil       Date:  1980-08       Impact factor: 3.966

10.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

View more
  6 in total

1.  Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy.

Authors:  Maya N Hatch; Kiin Kim; Gregorij Kurillo; Alina Nicorici; Craig M McDonald; Jay J Han
Journal:  Neuromuscul Disord       Date:  2019-05-23       Impact factor: 4.296

2.  Neuromuscular disorders and 2010: recent advances.

Authors:  Anna Sarkozy; Hanns Lochmüller
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

3.  Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Rabi Tawil; John T Kissel; Chad Heatwole; Shree Pandya; Gary Gronseth; Michael Benatar
Journal:  Neurology       Date:  2015-07-28       Impact factor: 9.910

4.  Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.

Authors:  Doris G Leung; John A Carrino; Kathryn R Wagner; Michael A Jacobs
Journal:  Muscle Nerve       Date:  2015-03-31       Impact factor: 3.852

5.  Motion sensor-acquired reachable workspace correlates with patient-reported upper extremity activities of daily living (ADL) function in facioscapulohumeral dystrophy.

Authors:  Maya N Hatch; Gregorij Kurillo; Vicky Chan; Jay J Han
Journal:  Muscle Nerve       Date:  2020-12-01       Impact factor: 3.852

6.  A 5-year clinical follow-up study from the Italian National Registry for FSHD.

Authors:  Liliana Vercelli; Fabiano Mele; Lucia Ruggiero; Francesco Sera; Silvia Tripodi; Giulia Ricci; Antonio Vallarola; Luisa Villa; Monica Govi; Louise Maranda; Antonio Di Muzio; Marina Scarlato; Elisabetta Bucci; Lorenzo Maggi; Carmelo Rodolico; Maurizio Moggio; Massimiliano Filosto; Giovanni Antonini; Stefano Previtali; Corrado Angelini; Angela Berardinelli; Elena Pegoraro; Gabriele Siciliano; Giuliano Tomelleri; Lucio Santoro; Tiziana Mongini; Rossella Tupler
Journal:  J Neurol       Date:  2020-08-19       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.